thalidomide has been researched along with goserelin in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Aragon-Ching, JB; Arlen, PM; Chatta, GS; Dahut, WL; Figg, WD; Gulley, JL; Higano, CS; Hussain, MH; Petrylak, DP; Sartor, O; Steinberg, SM | 1 |
| Aragon-Ching, JB; Arlen, PM; Chatta, GS; Dahut, WL; Figg, WD; Gulley, JL; Higano, CS; Hussain, MH; Parnes, H; Petrylak, DP; Sartor, O; Steinberg, SM; Wright, JJ | 1 |
| Aggen, DH; Dallos, MC; Drake, CG; Figg, WD; Hawley, JE; Hu, J; Lim, EA; Lopez-Bujanda, ZA; Pan, S; Stein, MN; Strope, JD | 1 |
1 review(s) available for thalidomide and goserelin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for thalidomide and goserelin
| Article | Year |
|---|---|
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Goserelin; Humans; Immunohistochemistry; Leuprolide; Male; Middle Aged; Neoplasm Staging; Probability; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Recovery of Function; Reference Values; Risk Assessment; Testosterone; Thalidomide; Treatment Outcome | 2008 |
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androgens; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Cross-Over Studies; Double-Blind Method; Goserelin; Humans; Leuprolide; Male; Middle Aged; Prostatic Neoplasms; Thalidomide | 2009 |
Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy.
Topics: Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Cohort Studies; Cytokines; Disease Progression; Double-Blind Method; Goserelin; Humans; Immune Tolerance; Immunity, Innate; Immunosuppressive Agents; Kallikreins; Leuprolide; Longitudinal Studies; Male; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Thalidomide | 2020 |